Literature DB >> 1394146

bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs.

T Miyashita1, J C Reed.   

Abstract

The S49.1 and WEHI7.2 murine lymphoid cell lines have been used extensively as models for investigations of programmed cell death ("apoptosis") induced by glucocorticoids such as dexamethasone. Infection of these thymus-derived T-cell lines with a recombinant retrovirus encoding the human M(r) 26,000 Bcl-2 oncoprotein resulted in marked resistance to DEX-mediated cell death and DNA degradation into oligonucleosomal fragments, without interfering with the ability of dexamethasone to suppress cellular proliferation and without lowering levels of glucocorticoid receptors. In contrast, high levels of p26-Bcl-2 production did not block cell killing and DNA fragmentation induced by H2O2, suggesting that the Bcl-2 impairs some but not all pathways for cell death in S49.1 and WEHI7.2 cells that are associated with the DNA fragmentation pattern typical of apoptosis. S49.1 and WEHI7.2 cells infected with bcl-2 but not control retrovirus also exhibited increased resistance to cell killing and DNA fragmentation induced by a wide variety of reagents, including the calcium ionophore ionomycin, the phorbol ester tetradecanoylphorbol acetate, the dihydrofolate reductase inhibitor methotrexate, the antimetabolite 1-beta-D-arabinofuranosylcytosine, and the microtubule inhibitor vincristine. These findings provide evidence that p26-Bcl-2 interferes with a pathway for cell death that is activated by multiple drugs used for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394146

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  81 in total

Review 1.  Antisense cancer therapy: the state of the science.

Authors:  D M Kushner; R H Silverman
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

Review 2.  A portrait of the Bcl-2 protein family: life, death, and the whole picture.

Authors:  M Pellegrini; A Strasser
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

3.  Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer?

Authors:  G Cox; R A Walker; S Muller; K R Abrams; W P Steward; K J O'Byrne
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

Review 4.  Mitochondria: a target for cancer therapy.

Authors:  Jeffrey S Armstrong
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

5.  Estrogen-induced apoptosis by inhibition of the erythroid transcription factor GATA-1.

Authors:  G A Blobel; S H Orkin
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

Review 6.  Mitochondrial medicine: pharmacological targeting of mitochondria in disease.

Authors:  J S Armstrong
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

7.  Context-dependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis.

Authors:  Haiming Dai; X Wei Meng; Sun-Hee Lee; Paula A Schneider; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2009-04-07       Impact factor: 5.157

Review 8.  Finally, An Apoptosis-Targeting Therapeutic for Cancer.

Authors:  Carlo M Croce; John C Reed
Journal:  Cancer Res       Date:  2016-09-30       Impact factor: 12.701

9.  Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells.

Authors:  R R Perry; Y Kang; B Greaves
Journal:  Ann Surg Oncol       Date:  1995-05       Impact factor: 5.344

10.  Bcl-2 sensitivity differentiates two pathways for motoneuronal death in the wobbler mutant mouse.

Authors:  M Coulpier; M P Junier; M Peschanski; P A Dreyfus
Journal:  J Neurosci       Date:  1996-10-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.